{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:13:36Z","timestamp":1788408816049,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novo Nordisk Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00459-3","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T15:48:26Z","timestamp":1785599306000},"page":"319-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Analysis of the Association Between Systemic Inflammation, Cardiovascular Events, and Economic Burden Among Patients with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease"],"prefix":"10.1007","volume":"15","author":[{"given":"Chi","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Ryali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Skaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey","family":"Robar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allegra","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"issue":"8","key":"459_CR1","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","volume":"151","author":"SS Martin","year":"2025","unstructured":"Martin SS, Aday AW, Allen NB, et al. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151(8):e41\u2013660. https:\/\/doi.org\/10.1161\/CIR.0000000000001303.","journal-title":"Circulation."},{"key":"459_CR2","doi-asserted-by":"publisher","DOI":"10.36922\/gtm025100024","author":"T Menon","year":"2025","unstructured":"Menon T, Chahil V, Patel D, Grancorvitz C, Vijayraghavan K. Inflammation and cardiovascular disease\u2014part II: anti-inflammatory therapy in cardiovascular disease. GTM. 2025. https:\/\/doi.org\/10.36922\/gtm025100024.","journal-title":"GTM"},{"key":"459_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al. Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J."},{"key":"459_CR4","doi-asserted-by":"publisher","DOI":"10.15420\/usc.2024.25","volume":"19","author":"A Mehta","year":"2025","unstructured":"Mehta A, Blumenthal RS, Gluckman TJ, Feldman DI, Kohli P. High-sensitivity C-reactive protein in atherosclerotic cardiovascular disease: to measure or not to measure? US Cardiol. 2025;19:e06. https:\/\/doi.org\/10.15420\/usc.2024.25.","journal-title":"US Cardiol."},{"issue":"38","key":"459_CR5","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1093\/eurheartj\/ehaf314","volume":"46","author":"S Romeo","year":"2025","unstructured":"Romeo S, Vidal-Puig A, Husain M, et al. Clinical staging to guide management of metabolic disorders and their sequelae: a European atherosclerosis society consensus statement. Eur Heart J. 2025;46(38):3685\u2013713. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf314.","journal-title":"Eur Heart J."},{"key":"459_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.100950","volume":"21","author":"L Lv","year":"2025","unstructured":"Lv L, Rajpura J, Liu M, et al. Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS). Am J Prev Cardiol. 2025;21:100950. https:\/\/doi.org\/10.1016\/j.ajpc.2025.100950.","journal-title":"Am J Prev Cardiol."},{"issue":"Suppl_1","key":"459_CR7","doi-asserted-by":"publisher","first-page":"A11398","DOI":"10.1161\/circ.146.suppl_1.11398","volume":"146","author":"M Nanna","year":"2022","unstructured":"Nanna M, Sloan L, Faurby M, et al. Abstract 11398: prevalence and characteristics of systemic inflammation in adults with atherosclerotic cardiovascular disease and chronic kidney disease: results from the National Health and Nutrition Examination Survey. Circulation. 2022;146(Suppl_1):A11398\u2013A11398. https:\/\/doi.org\/10.1161\/circ.146.suppl_1.11398.","journal-title":"Circulation"},{"issue":"10","key":"459_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005637","volume":"6","author":"CL Fanola","year":"2017","unstructured":"Fanola CL, Morrow DA, Cannon CP, et al. Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib\u2014Thrombolysis in Myocardial Infarction 52) Trial. J Am Heart Assoc. 2017;6(10):e005637. https:\/\/doi.org\/10.1161\/JAHA.117.005637.","journal-title":"J Am Heart Assoc."},{"issue":"1","key":"459_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","volume":"42","author":"PR Lawler","year":"2021","unstructured":"Lawler PR, Bhatt DL, Godoy LC, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42(1):113\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa099.","journal-title":"Eur Heart J."},{"key":"459_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2020.100130","volume":"4","author":"A Alfaddagh","year":"2020","unstructured":"Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: from mechanisms to therapeutics. Am J Prev Cardiol. 2020;4:100130. https:\/\/doi.org\/10.1016\/j.ajpc.2020.100130.","journal-title":"Am J Prev Cardiol."},{"issue":"6","key":"459_CR11","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","volume":"67","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. A test in context: high-sensitivity C-reactive protein. JACC. 2016;67(6):712\u201323. https:\/\/doi.org\/10.1016\/j.jacc.2015.11.037.","journal-title":"JACC."},{"issue":"13","key":"459_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1161\/01.CIR.103.13.1813","volume":"103","author":"PM Ridker","year":"2001","unstructured":"Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813\u20138. https:\/\/doi.org\/10.1161\/01.CIR.103.13.1813.","journal-title":"Circulation."},{"key":"459_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf295","author":"X Bian","year":"2025","unstructured":"Bian X, Wang HY, Guo Y, et al. Residual atherosclerotic risk in older patients with atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a). Age Ageing. 2025. https:\/\/doi.org\/10.1093\/ageing\/afaf295.","journal-title":"Age Ageing."},{"issue":"44","key":"459_CR14","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","volume":"45","author":"F Mazhar","year":"2024","unstructured":"Mazhar F, Faucon AL, Fu EL, et al. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease. Eur Heart J. 2024;45(44):4719\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehae557.","journal-title":"Eur Heart J."},{"issue":"1","key":"459_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20\u20138. https:\/\/doi.org\/10.1056\/NEJMoa042378.","journal-title":"N Engl J Med."},{"issue":"10384","key":"459_CR16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","volume":"401","author":"PM Ridker","year":"2023","unstructured":"Ridker PM, Bhatt DL, Pradhan AD, Glynn RJ, MacFadyen JG, Nissen SE. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. The Lancet. 2023;401(10384):1293\u2013301. https:\/\/doi.org\/10.1016\/S0140-6736(23)00215-5.","journal-title":"The Lancet."},{"issue":"12","key":"459_CR17","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med."},{"issue":"10118","key":"459_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0140-6736(17)32814-3","volume":"391","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018;391(10118):319\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(17)32814-3.","journal-title":"Lancet."},{"issue":"26","key":"459_CR19","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","volume":"344","author":"PM Ridker","year":"2001","unstructured":"Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959\u201365. https:\/\/doi.org\/10.1056\/NEJM200106283442601.","journal-title":"N Engl J Med."},{"issue":"9","key":"459_CR20","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.cir.98.9.839","volume":"98","author":"PM Ridker","year":"1998","unstructured":"Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98(9):839\u201344. https:\/\/doi.org\/10.1161\/01.cir.98.9.839.","journal-title":"Circulation"},{"issue":"46","key":"459_CR21","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","volume":"43","author":"PM Ridker","year":"2022","unstructured":"Ridker PM, Tuttle KR, Perkovic V, Libby P, MacFadyen JG. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy. Eur Heart J. 2022;43(46):4832\u201344. https:\/\/doi.org\/10.1093\/eurheartj\/ehac444.","journal-title":"Eur Heart J."},{"key":"459_CR22","doi-asserted-by":"publisher","DOI":"10.1161\/circinterventions.117.004981","author":"B Shah","year":"2017","unstructured":"Shah B, Baber U, Pocock SJ, et al. White blood cell count and major adverse cardiovascular events after percutaneous coronary intervention in the contemporary era: insights from the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017. https:\/\/doi.org\/10.1161\/circinterventions.117.004981.","journal-title":"Circ Cardiovasc Interv"},{"issue":"19","key":"459_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.036701","volume":"13","author":"N Talmor","year":"2024","unstructured":"Talmor N, Pillinger MH, Xia Y, Leonard A, Curovic F, Shah B. Neutrophil activation and adhesiveness in coronary artery disease: results from the COLCHICINE-PCI biomarker substudy. J Am Heart Assoc. 2024;13(19):e036701. https:\/\/doi.org\/10.1161\/JAHA.124.036701.","journal-title":"J Am Heart Assoc."},{"issue":"11","key":"459_CR24","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/cir.0000000000000678","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596\u2013646. https:\/\/doi.org\/10.1161\/cir.0000000000000678.","journal-title":"Circulation."},{"issue":"36","key":"459_CR25","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, et al. 2024 ESC guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC), endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J."},{"key":"459_CR26","unstructured":"Komodo Health Inc. Komodo Health, Inc. Accessed September 13, 2025, https:\/\/www.komodohealth.com\/solutions\/healthcare-map\/"},{"issue":"4","key":"459_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"issue":"19","key":"459_CR28","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C\u2013based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2102953.","journal-title":"N Engl J Med"},{"issue":"10289","key":"459_CR29","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/s0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(21)00520-1.","journal-title":"Lancet"},{"issue":"21","key":"459_CR30","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"},{"issue":"19","key":"459_CR31","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","volume":"87","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APHA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia. JACC. 2026;87(19):2624\u2013757. https:\/\/doi.org\/10.1016\/j.jacc.2025.11.016.","journal-title":"JACC"},{"issue":"11","key":"459_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012638","volume":"8","author":"JJ Carrero","year":"2019","unstructured":"Carrero JJ, Andersson Franko M, Obergfell A, Gabrielsen A, Jernberg T. hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study. J Am Heart Assoc. 2019;8(11):e012638. https:\/\/doi.org\/10.1161\/JAHA.119.012638.","journal-title":"J Am Heart Assoc."},{"issue":"11","key":"459_CR33","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/S1474-4422(25)00306-0","volume":"24","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard AT, Moorthy MV, Cook NR, et al. High-sensitivity C-reactive protein, LDL cholesterol, lipoprotein(a) and 30-year risk of stroke in healthy women: a prospective, longitudinal cohort study. Lancet Neurol. 2025;24(11):920\u201330. https:\/\/doi.org\/10.1016\/S1474-4422(25)00306-0.","journal-title":"Lancet Neurol."},{"issue":"11","key":"459_CR34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Medical Care."},{"key":"459_CR35","unstructured":"Komodo Health Inc. Imputing allowed amounts: Development and validation of an encounter-level allowed amount imputation model. https:\/\/knowledge.komodohealth.com\/hubfs\/Komodo_Imputing_Allowed_Amounts_White_Paper.pdf"},{"issue":"15","key":"459_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.121.024531","volume":"11","author":"CM Ballantyne","year":"2022","unstructured":"Ballantyne CM, Bays HE, Louie MJ, Smart J, Zhang Y, Ray KK. Factors associated with enhanced low-density lipoprotein cholesterol lowering with bempedoic acid. J Am Heart Assoc. 2022;11(15):e024531. https:\/\/doi.org\/10.1161\/jaha.121.024531.","journal-title":"J Am Heart Assoc."},{"key":"459_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.047","author":"GA Mensah","year":"2025","unstructured":"Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and cardiovascular disease: 2025 ACC Scientific Statement. J Am Coll Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.jacc.2025.08.047.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"459_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","volume":"135","author":"PC Robinson","year":"2022","unstructured":"Robinson PC, Terkeltaub R, Pillinger MH, et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease. Am J Med. 2022;135(1):32\u20138. https:\/\/doi.org\/10.1016\/j.amjmed.2021.07.025.","journal-title":"Am J Med."},{"issue":"7","key":"459_CR39","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa2405922","volume":"392","author":"SS Jolly","year":"2025","unstructured":"Jolly SS, d\u2019Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. N Engl J Med. 2025;392(7):633\u201342. https:\/\/doi.org\/10.1056\/NEJMoa2405922.","journal-title":"N Engl J Med."},{"issue":"21","key":"459_CR40","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","volume":"71","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, MacFadyen JG, Glynn RJ, et al. Inhibition of interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease. J Am Coll Cardiol. 2018;71(21):2405\u201314. https:\/\/doi.org\/10.1016\/j.jacc.2018.03.490.","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"459_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","volume":"149","author":"PM Ridker","year":"2024","unstructured":"Ridker PM, Lei L, Louie MJ, et al. Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance. Circulation. 2024;149(1):28\u201335. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066213.","journal-title":"Circulation."},{"issue":"1","key":"459_CR42","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1080\/13696998.2025.2542024","volume":"28","author":"JH Rudolfsen","year":"2025","unstructured":"Rudolfsen JH, Vukmirica J, Johansen P, R\u00f8der KL, Mortensen MB. Impact of systemic inflammation on healthcare resource utilization and cost in patients with atherosclerotic cardiovascular disease and chronic kidney disease. J Med Econ. 2025;28(1):1298\u2013306. https:\/\/doi.org\/10.1080\/13696998.2025.2542024.","journal-title":"J Med Econ."}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00459-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00459-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00459-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:24:13Z","timestamp":1788405853000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00459-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00459-3","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Chi Nguyen and Jeffrey R. Skaar are employees of Novo Nordisk Inc. and shareholders of Novo Nordisk A\/S. Jeffrey R. Skaar holds equity in Trinity Life Sciences. Allegra Kaufman, Carey Robar, Radha Ryali, Weilong Li, and Wing Chow were employees of Novo Nordisk Inc. at the time that the study was conducted. Allegra Kaufman is a shareholder of Novo Nordisk A\/S. Binita Shah has served as a consultant for Novo Nordisk Inc.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study used deidentified data and was, thus, exempt from institutional review board approval. The authors had permission from the database owner to use the data for the purpose of this study. The study was conducted in accordance with the ethical principles established in the Declaration of Helsinki and followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement for cohort studies.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}